Clinical trials: Hepatocholangiocarcinoma, open to volunteers
Hepatocholangiocarcinoma, Fibrolamellar Carcinoma
A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy…
- Conditions
- Hepatocholangiocarcinoma, Fibrolamellar Carcinoma, Hepatic Epithelioid Hemangioendothelioma, Hepatoblastoma
- Trial name
- FFCD-2205 (NCT06541652)
- Where
- 40 sites in France
- Volunteers
- 150 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Combined Hepatocellular-cholangiocarcinoma, Combined Hepatocellular Carcinoma and Cholangiocarcinoma
Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
This study focused on exploring new comprehensive treatment strategies for patients with unresectable combined hepatocellular-cholangiocarcinoma, classifying patients with CHC subtypes based on the combination of artificial…
- Conditions
- Combined Hepatocellular-cholangiocarcinoma, Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
- Trial name
- NCT06849180
- Testing
- Interventional therapies combined with or without systemic drugs
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Zhongda Hospital
Combined Hepatocellular and Cholangiocarcinoma
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
This is a single arm phase 2 study of Single Tremelimumab with Regular Interval Durvalumab (STRIDE) plus Gemcitabine and Cisplatin (GEMCIS) in locally advanced unresectable/metastatic combined hepatocellular-cholangiocarcinoma…
- Trial name
- NCT06855225
- Testing
- Tremelimumab, Durvalumab, Gemcitabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Mehmet Akce
Mixed Hepatocellular-cholangiocarcinoma
HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)
To evaluate HAIC combined with Camrelizumab plus rivoceranib for advanced mixed hepatocellular-cholangiocarcinoma (HCC-CCA).
- Trial name
- TASK-05 (NCT07105748)
- Testing
- Camrelizumab, Rivoceranib (Apatinib), HAIC
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fudan University